Cappanera Stefano, Palumbo Michele, Kwan Sherman H, Priante Giulia, Martella Lucia Assunta, Saraca Lavinia Maria, Sicari Francesco, Vernelli Carlo, Di Giuli Cinzia, Andreani Paolo, Mariottini Alessandro, Francucci Marsilio, Sensi Emanuela, Costantini Monya, Bruzzone Paolo, D'Andrea Vito, Gioia Sara, Cirocchi Roberto, Tiri Beatrice
Clinical Infectious Disease, Department of medicine, St. Maria Hospital, 05100 Terni, Italy.
Department of General Surgery, Royal Perth Hospital, Perth 6000, Australia.
J Clin Med. 2021 Jan 15;10(2):297. doi: 10.3390/jcm10020297.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that is responsible for coronavirus disease 2019 (COVID-19), which has rapidly spread across the world, becoming a pandemic. The "cytokine storm" (CS) in COVID-19 leads to the worst stage of illness, and its timely control through immunomodulators, corticosteroids, and cytokine antagonists may be the key to reducing mortality. After reviewing published studies, we proposed a Cytokine Storm Score (CSs) to identify patients who were in this hyperinflammation state, and at risk of progression and poorer outcomes. We retrospectively analyzed 31 patients admitted to Infectious Disease Department in "St. Maria" Hospital in Terni with confirmed SARS-CoV-2 infections, and analyzed the "CS score" (CSs) and the severity of COVID-19. Then we conducted a prospective study of COVID-19 patients admitted after the definition of the CSscore. This is the first study that proposes and applies a new score to quickly identify COVID-19 patients who are in a hyperinflammation stage, to rapidly treat them in order to reduce the risk of intubation. CSs can accurately identify COVID-19 patients in the early stages of a CS, to conduct timely, safe, and effect administration of immunomodulators, corticosteroids, and cytokine antagonists, to prevent progression and reduce mortality.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）是导致2019冠状病毒病（COVID-19）的病毒，该疾病已在全球迅速传播，成为大流行病。COVID-19中的“细胞因子风暴”（CS）导致疾病最严重阶段，通过免疫调节剂、皮质类固醇和细胞因子拮抗剂及时控制可能是降低死亡率的关键。在回顾已发表的研究后，我们提出了细胞因子风暴评分（CSs），以识别处于这种高炎症状态、有病情进展风险和较差预后的患者。我们回顾性分析了特尔尼“圣玛丽亚”医院传染病科收治的31例确诊SARS-CoV-2感染患者，并分析了“CS评分”（CSs）和COVID-19的严重程度。然后我们对CS评分定义后收治的COVID-19患者进行了前瞻性研究。这是第一项提出并应用新评分以快速识别处于高炎症阶段的COVID-19患者，以便迅速治疗以降低插管风险的研究。CSs可以在CS早期准确识别COVID-19患者，以便及时、安全且有效地给予免疫调节剂、皮质类固醇和细胞因子拮抗剂，防止病情进展并降低死亡率。
